Aiming to extend its vaccine empire, Pfizer (NYSE:PFE) has announced that its meningococcal vaccine (MenABCWY) candidate met primary and secondary endpoints in a Phase 3 study. The NCT04440163 study tested the vaccine in healthy individuals between the ages of 10 and 25. The vaccine candidate demonstrated non-inferiority to the licensed vaccines Trumenba and Menveo for…